Gene Therapy: Delivery Targeting

Abstract

Delivery targeting is a novel approach for the design and administration of therapeutic agents wherein the agent is rationally designed to localize to the site of disease in a self‐directed manner, usually via exploitation of unique biophysical properties of the diseased tissue.

Keywords: adenovirus; targeting; gene therapy; tropism modification; cancer

Figure 1.

A generalized adenovirus structure depicting major structural components of a wild‐type adenovirus capsid. Hexon is depicted as a hexagon with 12 homotrimers per capsid face (only 12 of 240 trimers are shown). The penton‐base, comprised of five subunits at each vertex, and trimeric fibre and pIX structures are shown. Adenovirus serotype 2 and 5 capsids contain a 36‐kilobase double‐stranded DNA genome (not shown).

Figure 2.

A schematic representation of genetically altered fibres for adenovirus targeting. (See text for specific examples of each genetic targeting approach and targeting moiety used.) (a) Trimeric wild‐type adenovirus fibre; tail, shaft and knob regions are shown. (b) Pseudotyped chimaeric fibre bearing an alternate human or animal serotype knob domain. (c) Fibre knob containing a C‐terminal targeting ligand. (d) Fibre knob with a constrained targeting peptide in the flexible H–I loop. (e) ‘de‐knobbed’ fibre containing a heterologous trimerization sequence and a C‐terminal targeting moiety.

Figure 3.

The two‐step adenovirus infection pathway. Shown are the basic steps of initial high‐affinity binding of the virion fibre to its primary cellular receptor, CAR, followed by endocytic cell entry mediated by penton‐base RGD interaction with cell‐surface integrins. Upon endosomal lysis, the partially dismantled virion is then released into the cytoplasm and is actively translocated to the nuclear pore complex where complete capsid degradation and viral genome import is accomplished.

Figure 4.

Adapter molecules for receptor‐specific adenovirus targeting. A generalized adapter molecule ablates native CAR‐based tropism and targets adenovirus to an alternate cellular receptor molecule. The dual specificity of the adapter molecule for both the adenovirus and the alternative receptor provides novel, CAR‐independent cell binding.

close

References

Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V and Curiel DT (2000) Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor‐positive cells. Journal of Virology 74(15): 6875–6884.

Douglas JT, Rogers BE, Rosenfeld ME et al. (1996) Targeted gene delivery by tropism–modified adenoviral vectors. Nature Biotechnology 14(11): 1574–1578.

Everts M, Kim‐Park SA, Preuss MA et al. (2005) Selective induction of tumor‐associated antigens in murine pulmonary vasculature using double‐targeted adenoviral vectors. Gene Therapy 12: 1042–1048.

Falgout B and Ketner G (1988) Characterization of adenovirus particles made by deletion mutants lacking the fiber gene. Journal of Virology 62(2): 622–625.

Goldman CK, Rogers BE, Douglas JT et al. (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Research 57(8): 1447–1451.

Hedley SJ, Auf der Maur A, Hohn S et al. (2006) An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Therapy 13(1): 88–94.

Izumi M, Kawakami Y, Glasgow JN et al. (2005) In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. Journal of Gene Medicine 7(12): 1517–1525.

Krasnykh V, Belousova N, Korokhov N, Mikheeva G and Curiel DT (2001) Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. Journal of Virology 75(9): 4176–4183.

Krasnykh V, Dmitriev I, Navarro JG et al. (2000) Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor‐independent cellular entry capacity. Cancer Research 60(24): 6784–6787.

Krasnykh VN, Mikheeva GV, Douglas JT and Curiel DT (1996) Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. Journal of Virology 70(10): 6839–6846.

Li J, Le LP, Sibley DA, Mathis JM and Curiel DT (2005) Genetic incorporation of HSV‐1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 338(2): 247–258.

Magnusson MK, Hong SS, Boulanger P and Lindholm L (2001) Genetic retargeting of adenovirus: novel strategy employing ‘deknobbing’ of the fiber. Journal of Virology 75(16): 7280–7289.

Mercier GT, Campbell JA, Chappell JD et al. (2004) A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proceedings of the National Academy of Sciences of the USA 101(16): 6188–6193.

Nakayama M, Both GW, Banizs B et al. (2006) An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR‐independent tropism and unique biodistribution in mice. Virology 350(1): 103–115.

Nicklin SA, Wu E, Nemerow GR and Baker AH (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy 12(3): 384–393.

Parks RJ (2005) Adenovirus protein IX: a new look at an old protein. Molecular Therapy 11(1): 19–25.

Reynolds PN, Zinn KR, Gavrilyuk VD et al. (2000) A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Molecular Therapy 2 (6): 562–578.

Shayakhmetov DM, Gaggar A, Ni S, Li ZY and Lieber A (2005) Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. Journal of Virology 79(12): 7478–7491.

Tao N, Gao GP, Parr M et al. (2001) Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Molecular Therapy 3(1): 28–35.

Ulasov IV, Tyler MA, Han Y, Glasgow JN and Lesniak MS (2007) Novel recombinant adenoviral vector that targets the interleukin‐13 receptor α2 chain permits effective gene transfer to malignant glioma. Human Gene Therapy 18(2): 118–129.

Vellinga J, de Vrij J, Myhre S et al. (2007) Efficient incorporation of a functional hyper‐stable single‐chain antibody fragment protein‐IX fusion in the adenovirus capsid. Gene Therapy 14(8): 664–670.

Vigne E, Mahfouz I, Dedieu JF et al. (1999) RGD inclusion in the hexon monomer provides adenovirus type 5‐based vectors with a fiber knob‐independent pathway for infection. Journal of Virology 73(6): 5156–5161.

Von Seggern DJ, Huang S, Fleck SK, Stevenson SC and Nemerow GR (2000) Adenovirus vector pseudotyping in fiber‐expressing cell lines: improved transduction of Epstein‐Barr virus‐transformed B cells. Journal of Virology 74(1): 354–362.

Wu H, Han T, Belousova N et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. Journal of Virology 79(6): 3382–3390.

Zhang Y and Bergelson JM (2005) Adenovirus receptors. Journal of Virology 79(19): 12125–12131.

Further Reading

Curiel DT and Douglas JT (eds) (2002) Adenoviral Vectors for Gene Therapy. New York: Academic Press.

Curiel DT and Douglas JT (eds) (2002) Vector Targeting for Therapeutic Delivery. Hoboken, NJ: Wiley‐Liss, Inc.

Glasgow JN, Everts M and Curiel DT (2006) Adenovirus targeting. Cancer Gene Therapy 13(9): 830–844.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Glasgow, Joel N, Beatty, Matthew S, and Curiel, David T(Sep 2007) Gene Therapy: Delivery Targeting. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0005746.pub2]